Financial Performance - The company's revenue for Q1 2024 was ¥530,735,953.60, representing a decrease of 14.26% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥200,985,602.32, with a significant increase in losses compared to the previous year[4] - Total operating revenue for Q1 2024 was approximately ¥530.74 million, a decrease from ¥619.00 million in Q1 2023, representing a decline of about 14.3%[21] - The net loss for Q1 2024 was approximately ¥202.27 million, compared to a net loss of ¥150.05 million in Q1 2023, indicating an increase in losses of about 34.8%[22] - The total comprehensive loss for Q1 2024 was approximately ¥190.57 million, compared to a loss of ¥170.22 million in Q1 2023, reflecting an increase in comprehensive losses of about 11.9%[22] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥218,660,254.19, indicating a decline in cash generation capabilities[4] - Cash flow from operating activities for Q1 2024 showed a net outflow of approximately ¥218.66 million, compared to a net outflow of ¥451.67 million in Q1 2023, indicating an improvement of about 51.6%[23] - The net cash flow from investing activities was -$167.33 million, compared to -$58.56 million in the previous period, indicating a significant increase in cash outflow for investments[24] - The total cash outflow from financing activities was $164.91 million, up from $19.56 million, reflecting a substantial rise in cash used for financing[24] - The ending balance of cash and cash equivalents decreased to $4.22 billion from $5.91 billion, showing a decline in liquidity[24] Assets and Liabilities - Total assets decreased by 4.91% to ¥10,038,331,079.32 compared to the end of the previous year[5] - Current assets decreased to ¥6,452,424,978.75 as of March 31, 2024, down 7.8% from ¥6,998,089,701.66 at the end of 2023[17] - Total liabilities decreased to ¥1,699,964,751.19, down 9.7% from ¥1,882,841,410.63[19] - Non-current assets increased slightly to ¥3,585,906,100.57, up from ¥3,558,997,459.97[18] - The company’s retained earnings showed a significant decline, with an unallocated profit of -¥662,422,660.38 compared to -¥461,437,058.06 in the previous year[19] Research and Development - Research and development (R&D) expenses totaled ¥202,456,558.64, accounting for 38.15% of revenue, an increase of 2.8 percentage points year-on-year[5] - Research and development expenses for Q1 2024 were approximately ¥202.46 million, a slight decrease from ¥218.80 million in Q1 2023, down by about 7.4%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,832[9] - The largest shareholder, Shenzhen BGI Technology Holdings Group Co., Ltd., held 36.81% of the shares[9] Business Strategy and Market Position - The company plans to enhance its marketing network and market expansion efforts, which has led to increased sales expenses[8] - The company maintains a steady growth trend in its core business despite challenging macroeconomic conditions[15] - The company emphasizes its industry-leading position and technological advantages to ensure stable growth in its main business[15] - The report highlights the company's resilience and risk resistance capabilities in its main business after returning to normal operations[15] Product Development and Innovation - The gene sequencing instrument segment achieved revenue of RMB 449.44 million, representing a year-on-year growth of 4%[15] - Overseas revenue for the gene sequencing instrument segment reached RMB 157.11 million, with a year-on-year increase of 19%[15] - The company launched the new generation sequencing reagent StandardMPS 2.0, aiming to enhance sequencing accuracy from Q30 to Q40, significantly reducing sequencing costs[16] - In April 2024, the company introduced the MGISEQ-2000RS FluoXpert multi-omics analyzer, the first of its kind in China with integrated pathology and sequencing capabilities[16] - The MGIDS-1000 enzyme-directed evolution screening system was launched, featuring high-throughput microfluidic droplet screening capabilities[16] - The company plans to introduce the new sequencing reagent across all mainstream sequencing platforms in the second half of 2024[16] Accounting and Reporting Changes - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[25]

Financial Performance - The company reported a net profit attributable to the parent company of negative RMB 83,404,440.16 as of December 31, 2023, leading to a decision not to distribute profits for the year [5]. - The company has not achieved profitability since its listing, indicating ongoing challenges in financial performance [3]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 25% year-over-year growth [12]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year 2023, representing a 25% year-over-year growth [16]. - The company’s operating revenue for 2023 was approximately ¥2.91 billion, a decrease of 31.19% compared to ¥4.23 billion in 2022 [22]. - The net profit attributable to shareholders for 2023 was approximately -¥607.5 million, representing a 129.98% decrease from ¥2.03 billion in 2022 [22]. - The cash flow from operating activities for 2023 was approximately -¥870.1 million, a decline of 161.22% compared to ¥1.42 billion in 2022 [22]. - The basic earnings per share for 2023 was -¥1.46, down 127.76% from ¥5.26 in 2022 [23]. - The company reported a quarterly operating revenue of ¥619 million in Q1 2023, with a net profit of -¥149.8 million [26]. - The company’s main business revenue for 2023 was CNY 286,717.83 million, a year-on-year decrease of 31.85% [181]. - The company reported a revenue of CNY 291,122.23 million, a decrease of 31.19% year-on-year [177]. - The net profit after deducting non-recurring gains and losses was CNY -68,283.07 million, a decrease of 358.54% year-on-year [177]. Research and Development - The company is investing in R&D for new technologies, with a budget allocation of 150 million RMB for the upcoming year [12]. - Investment in R&D increased by 15%, totaling 150 million RMB, focusing on innovative technologies and product development [16]. - The company increased its R&D investment as a percentage of operating revenue to 31.26% in 2023, up from 19.25% in 2022, reflecting a 12.01 percentage point increase [24]. - The company achieved a total R&D investment of approximately ¥909.98 million, representing an increase of 11.74% compared to the previous year [135]. - R&D investment accounted for 31.26% of total revenue, an increase of 12.01 percentage points from the previous year [135]. - The company applied for 461 new patents and software copyrights during the reporting period, with a total of 1,945 applications to date [134]. - The company received 283 patents and software copyrights, bringing the total to 1,062 valid patents and copyrights [134]. - The company has developed multiple core technologies in gene sequencing, including DNBSEQ sequencing technology and automated sample processing technology [128]. Market Expansion and Strategy - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 30% [12]. - Market expansion plans include entering three new international markets, aiming for a 15% market share in each by the end of the next fiscal year [12]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of acquiring two companies within the next 18 months [12]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025 [16]. - The company aims to enhance its brand visibility and product accessibility through various promotional activities and collaborations with key ecosystem partners [47]. - The company is actively expanding its market presence and product offerings in the life sciences and biotechnology sectors [65]. - The company has established a global partnership ecosystem to maximize commercial potential, collaborating with major research institutions and clinical enterprises for advanced technology applications [154]. Operational Efficiency and Risk Management - The company has outlined various operational risks in its management discussion, emphasizing the importance of risk management strategies [3]. - The company is implementing new strategies to improve operational efficiency, aiming for a 5% reduction in costs by the end of 2024 [16]. - The company plans to enhance its marketing network and optimize inventory management to mitigate risks [171]. - The company is closely monitoring international macroeconomic changes to manage foreign exchange risks effectively [172]. - The company has implemented measures to manage accounts receivable risks, but potential delays in collections could lead to significant bad debt losses [170]. Compliance and Governance - The audit report issued by KPMG Huazhen confirmed the financial statements are free from material misstatements, providing assurance on the accuracy of the financial reporting [4]. - There are no non-operational fund occupations by controlling shareholders or related parties, ensuring financial integrity [7]. - The company has not reported any violations of decision-making procedures regarding external guarantees, maintaining compliance with regulations [7]. - The company is committed to compliance with GDPR regulations, ensuring data protection and privacy for its users [15]. - The company emphasizes data privacy and security, adhering to GDPR and local regulations, ensuring the legality and transparency of data management processes [62]. Product Development and Innovation - The company launched the ultra-high throughput sequencer DNBSEQ-T20×2 and received regulatory approval for the DNBSEQ-G99, enhancing its product offerings in the clinical-grade sequencing market [31]. - The company launched the DCS Lab multi-omics frontier laboratory program, aiming to establish 10 labs globally to enhance research efficiency in genomics, cellomics, and spatiotemporal omics [53]. - The company launched the MGISP-NEX fully automated nucleic acid extraction and purification instrument, capable of processing liquid volumes from 50μL to 5000μL, enhancing efficiency and reducing manual operations in various research fields [39]. - The company launched the MGISP-NEX product during the reporting period, which integrates magnetic rod and liquid transfer technology for fully automated nucleic acid extraction from complex samples [82]. - The company has developed nucleic acid extraction technologies for various biological samples, achieving international leading levels with the launch of MGIEasy extraction kits [141]. - The company launched the upgraded MGISP-Smart 8 product, which has been successfully implemented by multiple partners [46]. Challenges and Risks - The company faced a significant decline in demand for laboratory automation products due to social environmental factors, leading to a decrease in revenue and a net profit loss during the reporting period [159]. - The company faces risks related to product upgrades and technology updates, which require significant R&D investment and may lead to low ROI if new products do not meet market expectations [160]. - Core talent loss and technology leakage pose significant risks, as the company relies on skilled personnel for R&D, and losing them could delay projects and diminish competitive advantages [161]. - The company has faced patent and trademark infringement lawsuits from competitors, which may limit its market expansion in affected regions like France and Turkey [162]. - The global life sciences market is increasingly competitive, with major players like Illumina and Thermo Fisher dominating the gene sequencing market, which poses challenges for the company in gaining market share [163].

证券代码：688114 证券简称：华大智造 公告编号：2024-023 深圳华大智造科技股份有限公司 关于向金融机构申请综合授信额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳华大智造科技股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日 召开第二届董事会第五次会议，审议通过了《关于向金融机构申请综合授信额度 的议案》，具体情况如下： 为满足公司及子公司生产经营和发展的需要，公司及全资或控股子公司拟向 银行等金融机构申请总额不超过人民币 35 亿元的综合授信额度，授信业务包括 但不限于流动资金贷款、固定资产贷款、项目贷款、承兑汇票、保函、信用证、 票据贴现等综合业务，具体授信业务品种、额度和期限，以金融机构最终核定为 准。授信申请工作中，金融机构如需要提供相关增信措施，公司将在履行相关审 议批准程序后在上述额度内提供相应保证、质押、抵押或第三方担保。 以上授信额度不等于公司的实际融资金额，具体融资金额将视公司运营资金 的实际需求来合理确定，具体融资的种类、金额、利率、融资期限等以签署的具 体 ...

KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 +86 (10) 8518 5111 Fax Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街1号 东方广场毕马威大楼8层 邮政编码:100738 电话 +86(10)8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 深圳华大智造科技股份有限公司 内部控制审计报告 深圳华大智造科技股份有限公司 内部控制审计报告 毕马威华振审字第 2408820 号 深圳华大智造科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了深圳 华大智造科技股份有限公司 (以下简称 "贵公司"）2023 年 12 月 31 日的财务报告内部控制的 有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 ...

（一） 公司董事会基本构成 深圳华大智造科技股份有限公司 2023 年度独立董事述职报告 本人孙健，作为深圳华大智造科技股份有限公司（以下简称"公司"）的独 立董事，2023 年度，本人严格按照《中华人民共和国公司法》（以下简称《公司 法》）、《中华人民共和国证券法》《上市公司治理准则》《上市公司独立董事规则》 等法律法规、规范性文件，以及《公司章程》和《独立董事工作制度》等公司内 部制度的相关规定，忠实履行职责，在董事日常工作及重要决策中尽职尽责，并 对董事会的相关事项发表了独立意见，从公司整体利益出发，发挥了独立董事的 应有作用，维护了公司和全体股东特别是中小股东的合法权益。现将 2023 年度 履行独立董事职责工作情况汇报如下： 一、独立董事的基本情况 报告期内，公司董事会由 12 名董事组成，其中独立董事 4 人，占董事会人 数三分之一，符合相关法律法规及公司制度的规定。 （二） 个人工作履历、专业背景以及兼职情况 本人孙健，1982 年出生，无境外居留权。2009 年 6 月毕业于中国人民大学 商学院，获得会计学博士学位，2017 年获评会计学教授，2019 年获评博士生导 师。2009 年 7 月 ...

根据公司独立董事自查及其在公司的履职情况，董事会认为公司独立董事均 符合胜任独立董事的职责要求，其未在公司担任除独立董事以外的任何职务，也 未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系 或其他妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况，符 合《上市公司独立董事管理办法》等法律法规及《公司章程》中关于独立董事的 任职资格及独立性的相关要求。 深圳华大智造科技股份有限公司 董事会 2024 年 4 月 26 日 深圳华大智造科技股份有限公司 董事会对独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》的规定，独立董事应当每年对独立性情况进行自 查，并将自查情况提交董事会。董事会应当每年对在任独立董事独立性情况进行 评估并出具专项意见，与年度报告同时披露。基于此，深圳华大智造科技股份有 限公司（以下简称"公司"）董事会就公司在任独立董事李正、许怀斌、杨祥良、 孙健 2023 年度的独立性情况进行评估并出具如下专项意见： ...

证券代码：688114 证券简称：华大智造 公告编号：2024-017 深圳华大智造科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2024 年 3 月，深圳华大智造科技股份有限公司（以下简称"公司"）通过 上海证券交易所交易系统以集中竞价交易方式累计回购股份 382,356 股，占公司 总股本 415,637,624 股的比例为 0.0920%，回购成交的最高价为 69.51 元/股，最 低价为 58.68 元/股，支付的金额为人民币 25,157,517.17 元（不含交易费用）。 截至 2024 年 3 月 31 日，公司通过上海证券交易所交易系统以集中竞价交 易方式累计回购公司股份 3,560,082 股，占公司总股本 415,637,624 股的比例为 0.8565%，回购成交的最高价为 85.99 元/股，最低价为 58.68 元/股，支付的资金 总额为人民币 264,982,922.73 元（不含交易费用）。 一、回购股份的基本情 ...

证券代码：688114 证券简称：华大智造 公告编号：2024-016 深圳华大智造科技股份有限公司 2024 年 2 月，公司通过上海证券交易所交易系统以集中竞价交易方式累计 回购股份 829,267 股，占公司总股本 415,637,624 股的比例为 0.1995%，回购成交 的最高价为76.71元/股，最低价为60.90元/股，支付的金额为人民币55,408,947.64 元（不含交易费用）。 一、回购股份的基本情况 2023 年 10 月 10 日，公司召开第二届董事会第一次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上 海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通 股（A 股）股票。回购的股份将在未来适宜时机全部用于员工持股计划或股权激 励，回购价格不超过人民币 125.00 元/股（含），回购资金总额不低于人民币 25,000 万元（含），不超过人民币 50,000 万元（含），回购期限为自公司董事会审议 通过回购股份方案之日起 12 个月内。 具体内容详见公司分别于 2023 年 10 月 12 日、2023 年 10 月 ...

[Table_Header] 公司点评●医疗器械 2024 年 02 月 28 日 [Table_Title] [Table_StockCode] 业绩符合预期，海外布局加速推进 华大智造(688114) [Table_InvestRank] 推荐 核心观点： (维持) 分析师 [Table⚫_ Sum事m件ar：y] 公司发布 2023 年度业绩快报，全年实现营业收入 29.12 亿元（- [程Ta培b le_Authors] 31.17%），归母净利润-5.97亿元（-129.46%），扣非净利润-6.71亿元（- ：021-20257805 354.01%）。2023年 Q4实现营业收入 7.08亿元（-24.74%），归母净利润 -3.99亿元，扣非净利润-4.28亿元。 ：chengpei_yj@chinastock.com.cn ⚫ 核心业务保持高速增长，减值计提影响表观利润。实验室自动化产品 分析师登记编码：S0130522100001 需求萎缩导致公司 2023年表观收入显著下滑，但基因测序仪业务仍保持 研究助理：孟熙 高速增长，营业收入实现了同比 2022 年 30.57%的增长，主要基 ...

Investment Rating - The report assigns an "Accumulate" rating to the company, indicating a positive outlook for future performance [4]. Core Insights - The company has experienced rapid growth in its gene sequencing instrument business, with a year-on-year sales revenue increase of approximately 30% in 2023. The company is actively expanding its overseas market, particularly in Europe and the United States, where its full line of gene sequencing products began sales in early 2023, contributing to significant revenue growth in the U.S. [2]. - The company anticipates a net loss attributable to shareholders of between -6.87 billion to -5.78 billion yuan for 2023, a decline of 128.52% to 133.90% year-on-year. The fourth quarter of 2023 is expected to see a net loss of -4.89 billion to -3.80 billion yuan [3]. - The report highlights that the company's profit is under pressure due to several factors, including a high base from non-recurring gains in 2022, a decline in revenue from laboratory automation products, increased R&D investments, and higher sales expenses due to international expansion efforts [3]. Financial Summary - The company’s projected financials for 2023-2025 include: - Revenue: 29.21 billion yuan in 2023, 36.94 billion yuan in 2024, and 46.21 billion yuan in 2025, with corresponding year-on-year growth rates of -30.9%, 26.5%, and 25.1% respectively [3]. - Net profit: Expected to be -6.18 billion yuan in 2023, -1.64 billion yuan in 2024, and a return to profitability with a net profit of 1.37 billion yuan in 2025 [3]. - The projected price-to-sales (PS) ratios for 2024 and 2025 are 10.45X and 8.26X, respectively, indicating a potential for valuation improvement as the company returns to profitability [3].